Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy and safety of necitumumab (neci) in East Asian (EA) patients (pts) with stage IV squamous non-small-cell lung cancer (NSCLC): a subanalysis of the SQUIRE trial

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Keunchil Park

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

K. Park1, E.K. Cho2, M. Bello3, M.A. Ahn4, S. Thongprasert5, E. Song6, V. Soldatenkova7, H. Depenbrock8, T. Puri9, M. Orlando10

Author affiliations

  • 1 Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2 Gachon University Gil Medical Center, Namdong-gu, Incheon/KR
  • 3 St. Luke's Medical Center, 1102, Quezon City/PH
  • 4 Samsung Medical Center, Kangnam-Gu, Seoul/KR
  • 5 Faculty Of Medicine, Maharaj Nakorn Chiang Mai, Chiang Mai University, Chiang Mai/TH
  • 6 Chonbuk National University Hospital, Deokjin-gu, Jeon Ju/KR
  • 7 Statistics Oncology, Lilly Deutschland GmbH, Bad Homburg/DE
  • 8 Medical Oncology, Lilly Deutschland GmbH, 61352 - , Bad Homburg/DE
  • 9 Eli Lilly And Company, Haryana, Gurgaon/IN
  • 10 Eli Lilly Interamerica Inc., Tronador 4890, Buenos Aire/AR
More

Resources

Aim/Background

The SQUIRE trial showed that neci added to gemcitabine + cisplatin (GC) improves overall survival (OS) in advanced squamous NSCLC pts. We report results of the EA subgroup.

Variable EA Non-EA
Neci + GC GC Neci + GC GC
Efficacy, median mos (95% CI) n = 43 n = 41 n = 502 n = 507
OS 12.0 (7.3, 15.2) 12.2 (5.5, 14.7) 11.5 (10.5, 12.6) 9.8 (8.8, 11.1)
HR (95% CI)* 0.805 (0.484, 1.341) 0.839 (0.730, 0.964)
PFS 5.6 (4.7, 6.4) 5.3 (2.8, 5.6) 5.7 (5.6, 6.0) 5.5 (4.8, 5.6)
HR (95% CI)* 0.720 (0.439, 1.180) 0.862 (0.749, 0.993)
Safety, n (%) n = 41 n = 39 n = 497 n = 502
Treatment- emergent AE 41 (100) 37 (94.9) 492 (99.0) 492 (98.0)
Neci related 30 (73.2) 0 378 (76.1) 0
SAE 27 (65.9) 20 (51.3) 230 (46.3) 183 (36.5)
Neci related 1 (2.4) 0 31 (6.2) 0
Grade ≥3 36 (87.8) 25 (64.1) 352 (70.8) 308 (61.4)
Neci related 5 (12.2) 0 84 (16.9) 0
With outcome death 7 (17.1) 3 (7.7) 59 (11.9) 54 (10.8)
Neci related 0 (0) 0 2 (0.4) 0

* neci + GC/GC.

Methods

Eligible pts were chemotherapy naive, ≥18 years, had stage IV squamous NSCLC, ECOG performance status 0-2, and unknown EGFR mutation status. Pts were randomly assigned to ≤ six 3-week cycles of G (1250 mg/m2) C (75 mg/m2) ± neci (800 mg). OS (median [months], 95% CI) and progression-free survival (PFS) of pts from EA (Korea, Taiwan, Singapore, Thailand, and Philippines) and non-EA countries treated with neci + GC or GC were estimated using the Kaplan-Meier method. Hazard ratios (HR) and 95% CIs of neci + GC vs GC were estimated from stratified Cox proportional hazards models.

Results

Baseline characteristics were similar between EA groups. OS and PFS were improved in EA pts treated with neci + GC vs GC, and were similar for EA vs non-EA pts treated with neci + GC (Table). The percentages of serious adverse events (SAEs), AEs Grade ≥3, and AEs with outcome of death were higher in EA pts treated with neci + GC vs GC, and in EA vs non-EA pts treated with neci + GC (Table). The percentages of AEs causally related to neci only were similar in EA and non-EA pts (Table).

Conclusions

The efficacy of neci in EA pts with advanced squamous NSCLC was consistent with those in non-EA pts. The overall percentage of AEs with neci + GC was higher in EA pts than in non-EA pts; however, the AEs related to neci were similar.

Clinical trial identification

NCT00981058

Disclosure

K. Park: consulted/advised for Astellas, Astra-Zeneca, AVEO, and Boehringer Ingelheim. M.-J. Ahn: consulted/advised for Eli Lilly and Company. V. Soldatenkova, H. Depenbrock, T. Puri, M. Orlando: employee of Eli Lilly and Company and own shares in Eli Lilly Pty Ltd. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings